Litigation Details for Astellas Pharma Inc. v. Fresenius Kabi USA LLC (D. Del. 2015)

Astellas Pharma Inc. v. Fresenius Kabi USA LLC (D. Del. 2015)

Docket		Date Filed	2015-01-23
Court	District Court, D. Delaware	Date Terminated	2016-04-01
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Parties	ASTELLAS PHARMA US INC.
Patents	6,774,104
Attorneys	David A. Bilson
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Details for Astellas Pharma Inc. v. Fresenius Kabi USA LLC (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-01-23				External link to document
2015-01-22	4		Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,107,458; 6,774,104 B1;. (els) (Entered…2015 1 April 2016 1:15-cv-00080 830 Patent None District Court, D. Delaware	External link to document
2015-01-22	42		Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,107,458; 6,774,104. (ntl) (Entered…2015 1 April 2016 1:15-cv-00080 830 Patent None District Court, D. Delaware	External link to document

Astellas Pharma Inc. v. Fresenius Kabi USA LLC, 1:15-cv-00080: Litigation Summary and Patent Analysis

Last updated: August 27, 2026

Astellas Pharma Inc. sued Fresenius Kabi USA LLC in the U.S. District Court for the District of Delaware under the Hatch-Waxman Act after Fresenius filed an abbreviated new drug application seeking approval to market generic micafungin sodium for injection, the generic equivalent of Astellas' Mycamine. The case was a Paragraph IV patent dispute involving Astellas' micafungin patent estate. The action did not produce a reported trial judgment or a published claim-construction decision. Its commercial importance was tied to the timing of generic micafungin entry after expiration of the asserted patents and regulatory exclusivities. [1]

What drug was involved in Astellas v. Fresenius Kabi?

The dispute involved micafungin sodium for injection, marketed by Astellas as Mycamine.

Product and regulatory profile

Item	Detail
Brand	Mycamine
Active ingredient	Micafungin sodium
Dosage form	Intravenous powder for solution
Therapeutic category	Echinocandin antifungal
Sponsor	Astellas Pharma Inc.
FDA application	NDA 021506
Generic pathway	ANDA filing under Hatch-Waxman
Defendant	Fresenius Kabi USA LLC
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:15-cv-00080
Case type	Paragraph IV patent infringement action

Micafungin is used to treat invasive candidiasis, esophageal candidiasis and prophylaxis of Candida infections in hematopoietic stem-cell transplant patients. Its intravenous formulation made the product commercially relevant to injectable-generic manufacturers such as Fresenius Kabi. [2]

What patents protected Mycamine and micafungin sodium?

The core Mycamine patent estate originated from Astellas and its predecessor companies and covered micafungin compounds and related echinocandin technology.

Principal patent families

The micafungin patent portfolio included patents directed to:

• Echinocandin compounds and derivatives;
• Micafungin sodium and pharmaceutical compositions;
• Injectable formulations;
• Methods of treating fungal infections; and
• Processes associated with producing or formulating the active ingredient.

The principal U.S. patent associated with micafungin was U.S. Patent No. 6,107,458. That patent covered echinocandin compounds and formed part of the exclusivity structure supporting Mycamine. Other patents in the broader estate included U.S. Patent Nos. 6,281,336, 6,458,767, 6,670,340 and later formulation or composition patents. The precise patents asserted against Fresenius must be read from the complaint and docket filings because Orange Book listings and litigation assertions do not always contain the entire patent portfolio. [1][3]

Patent protection by subject matter

Protection category	Relevance to Mycamine
Active compound patents	Covered micafungin or related echinocandin structures
Composition patents	Covered micafungin sodium and pharmaceutical compositions
Formulation patents	Addressed injectable presentations, stability and excipient systems
Method-of-use patents	Covered antifungal treatment and prophylaxis indications
Manufacturing patents	Could create additional barriers if the generic process practiced protected claims

The commercial strength of the estate depended on whether the asserted claims covered the active ingredient itself or only a narrower formulation or manufacturing process. Compound claims generally create a stronger barrier because an ANDA product cannot avoid infringement merely by changing excipients. Process and formulation claims are more vulnerable to non-infringement positions.

What were Fresenius Kabi's Paragraph IV allegations?

Fresenius' ANDA filing triggered the patent litigation because it certified that the relevant Astellas patents were invalid, unenforceable or would not be infringed by the proposed generic product.

A Paragraph IV certification permits an ANDA applicant to challenge listed patents before expiration. Once the brand company receives notice, it has 45 days to file an infringement action. A timely suit generally creates a 30-month stay preventing FDA approval of the ANDA, subject to statutory exceptions and court orders. [4]

The likely defenses in the case were the standard Hatch-Waxman defenses:

1. Non-infringement, based on the formulation, manufacturing process or proposed labeling;
2. Invalidity for anticipation or obviousness;
3. Lack of written description or enablement;
4. Patent-term or Orange Book listing challenges; and
5. In some cases, unenforceability based on inequitable conduct.

The docket does not show a reported merits decision resolving these issues. As a result, the case does not establish binding precedent on the validity or scope of Astellas' micafungin patents.

When did Mycamine lose exclusivity?

Mycamine's effective exclusivity was determined by several overlapping dates rather than by a single patent expiration date.

Exclusivity timeline

Event	Timing
Original FDA approval of Mycamine	2005
Core compound patent protection	Extended into the late 2010s through patent-term adjustment and related rights
Astellas' Delaware action against Fresenius	2015
Core patent expiration period	Approximately 2019, subject to patent-specific adjustment and pediatric exclusivity
Generic micafungin approvals	Began after the principal patent barriers ended
Commercial generic competition	Emerged around the 2019-2020 period

Patent expiration must be distinguished from FDA regulatory exclusivity. Mycamine received pediatric exclusivity, which can add six months to qualifying patent and regulatory periods. The effective generic-entry date therefore depended on the specific patent, any patent-term adjustment, pediatric extension and the terms of any settlement agreement.

The case itself should not be treated as proof that all Mycamine patents expired on the same date. The estate contained multiple patents with different filing histories and expiration calculations.

What was the litigation status and outcome?

Astellas filed the action in 2015 in the District of Delaware. The case was resolved without a reported trial opinion, Federal Circuit decision or published judgment addressing patent validity or infringement.

Procedural assessment

Issue	Status
Complaint	Filed by Astellas against Fresenius Kabi
Legal basis	ANDA-related patent infringement
Trial	No reported trial decision
Claim construction	No widely cited published Markman ruling
Invalidity ruling	None reported
Infringement ruling	None reported
Settlement	The case record indicates resolution without a public merits opinion
Public settlement terms	Not publicly established in the reported court record
Precedential value	Limited; no reported holding on the asserted claims

A dismissal or resolution of this type commonly reflects a confidential Hatch-Waxman settlement. Such agreements frequently establish a licensed generic-entry date, supply rights, launch conditions or restrictions on authorized generic competition. A confidential resolution cannot be used to infer that Astellas' patents were necessarily strong or that Fresenius' invalidity defenses were weak.

Did the case involve a generic launch settlement?

The publicly available docket does not provide a reported settlement opinion setting out the commercial terms. Therefore, the precise Fresenius entry date, any authorized-generic arrangement and any restrictions on launch cannot be treated as established from the docket alone.

For commercial analysis, the important distinction is between:

• A dismissal following a license that permits entry before patent expiration;
• A dismissal following a no-entry-until-expiration agreement;
• A settlement involving a contingent launch date; and
• A termination after Fresenius abandoned or amended its ANDA.

Each structure produces a different competitive forecast. Without published settlement terms, the case supports a finding of negotiated resolution, not a precise contractual launch date.

What was the Orange Book status of Mycamine?

Mycamine was listed in the FDA Orange Book with patents associated with the approved micafungin product. Orange Book listing created the statutory framework for Fresenius' Paragraph IV challenge and the resulting 30-month approval stay. [3]

Orange Book implications

The Orange Book did not necessarily capture every patent that could be asserted against an ANDA applicant. Listed patents generally must claim the drug substance, drug product or an approved method of use. Manufacturing patents ordinarily do not qualify for Orange Book listing but may still be asserted in separate litigation if the generic manufacturing process practices the claims.

This distinction matters because a Fresenius ANDA challenge could address the listed product or use patents while leaving separate process patents outside the automatic Orange Book stay mechanism.

How strong was Astellas' micafungin patent estate?

Astellas' position was strongest where the asserted claims covered micafungin or micafungin sodium as a composition of matter. Those claims would be difficult for a generic applicant to design around while marketing the same active ingredient.

The estate was weaker where protection depended on:

• A narrow excipient combination;
• A particular concentration or reconstitution condition;
• A specific manufacturing step;
• A method-of-use limitation not included in the generic label; or
• A claim vulnerable to prior-art references involving echinocandin chemistry.

Patent-strength assessment

Patent feature	Risk assessment for Astellas
Composition-of-matter claim	Strong barrier if valid and infringed
Broad micafungin formulation claim	Moderate to strong
Narrow injectable formulation claim	More susceptible to design-around
Method-of-use claim	Dependent on generic labeling and induced-infringement evidence
Manufacturing-process claim	Potentially difficult to prove without discovery
Late-filed secondary patent	Greater validity and obviousness risk

The absence of a merits decision means the litigation did not validate the asserted patents judicially. The commercial outcome was instead controlled by negotiated resolution and the expiration of the relevant patent rights.

What generic-entry risks existed for Astellas?

The main risk was substitution by lower-priced injectable micafungin products after the core patent barriers ended. Hospital and institutional purchasers are particularly sensitive to generic injectable competition because procurement decisions often depend on formulary placement, supply reliability and contract pricing.

Competitive risks

• Generic micafungin could erode Mycamine volume rapidly after multiple ANDA approvals.
• Injectable competition could reduce average selling prices even before full generic substitution.
• Astellas' ability to preserve pricing would depend on supply continuity and hospital contracts.
• Formulation or manufacturing patents could delay individual competitors but would not necessarily prevent market entry by the broader generic class.
• Any authorized-generic arrangement could moderate price erosion while protecting some sales volume.

Micafungin also competed with other echinocandins, including anidulafungin and caspofungin. This reduced the strategic value of relying solely on patent protection because hospitals already had therapeutic alternatives.

How did this case compare with other Astellas patent disputes?

The Fresenius case differed from Astellas disputes involving high-revenue oral products such as Xtandi, Vesicare or Myrbetriq.

Factor	Mycamine/Fresenius dispute	Major oral-product disputes
Dosage form	Injectable	Tablet or capsule
Generic manufacturer profile	Injectable specialists	Broad oral-generic manufacturers
Primary commercial issue	Hospital and institutional purchasing	Pharmacy substitution and payer formularies
Patent value	Compound plus formulation protection	Compound, polymorph, formulation and method-of-use claims
Launch economics	Lower unit price but institutional volume	Larger retail substitution opportunity
Biosimilar risk	None	None for small-molecule drugs

There was no biosimilar pathway issue. Micafungin is a small-molecule drug, so competition proceeded through the ANDA pathway rather than through a 351(k) biosimilar application.

What licensing and settlement issues matter for investors?

The key commercial question is whether the resolution granted Fresenius a defined license or merely ended the action. A license could have preserved Astellas' control over the generic-entry timetable while converting litigation risk into a royalty or authorized-supply opportunity.

Relevant diligence points include:

• The agreed generic-entry date;
• Whether Fresenius received a license to listed patents;
• Whether the agreement covered future patents;
• Whether Astellas retained authorized-generic rights;
• Whether Fresenius could launch at risk;
• Whether the agreement contained supply or manufacturing terms; and
• Whether the settlement was submitted to the Federal Trade Commission under the pharmaceutical agreement reporting rules.

Because the public docket does not report the settlement terms, the litigation supports only a resolution-based assessment. It does not support a precise calculation of settlement value, royalty rate or Fresenius' launch timing.

Key Takeaways

• Astellas Pharma Inc. v. Fresenius Kabi USA LLC, No. 1:15-cv-00080, was a District of Delaware Hatch-Waxman case involving generic micafungin sodium for injection, the generic equivalent of Mycamine.
• Fresenius challenged Astellas' micafungin patent protection through the Paragraph IV process.
• U.S. Patent No. 6,107,458 was a principal patent associated with the micafungin estate, supported by related compound, composition and formulation patents.
• The case ended without a reported merits decision, published claim-construction ruling or appellate opinion.
• The precise settlement terms and generic-entry date are not established in the reported public record.
• Mycamine's effective exclusivity ended as the relevant patents and pediatric extensions expired, with generic micafungin competition emerging around the 2019-2020 period.
• The case had no biosimilar component because micafungin is a small-molecule drug regulated through the ANDA pathway.
• Astellas' strongest protection was associated with claims covering the active compound or micafungin composition. Narrow formulation and process claims presented greater design-around risk.

FAQs About Astellas v. Fresenius Kabi

Was Astellas v. Fresenius Kabi a Paragraph IV lawsuit?

Yes. The action was an ANDA-related patent infringement case arising from Fresenius Kabi's challenge to patents associated with generic micafungin sodium for injection.

Did Fresenius Kabi receive FDA approval for generic micafungin?

Fresenius Kabi was among the companies pursuing generic injectable products in this market. FDA approval timing must be assessed by specific ANDA and product listing rather than inferred solely from the civil docket.

Did the court rule that Astellas' Mycamine patents were valid?

No reported opinion in the case adjudicated validity. The case did not produce a published merits holding sustaining or invalidating the asserted patents.

Were Mycamine's patents composition patents or formulation patents?

The portfolio included compound and composition protection, along with related formulation, use and manufacturing technology. The principal commercial barrier was the protection surrounding micafungin and micafungin sodium.

Did Mycamine have biosimilar competition?

No. Mycamine is a small-molecule drug. Its generic competitors used the ANDA pathway rather than the biosimilar pathway.

References

1. U.S. District Court for the District of Delaware. (2015). Astellas Pharma Inc. v. Fresenius Kabi USA LLC, No. 1:15-cv-00080. PACER docket record.
2. U.S. Food and Drug Administration. (n.d.). Mycamine (micafungin sodium) prescribing information.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
4. U.S. Code, 21 U.S.C. § 355(j).